Plain-English translation of NCT07281716 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing and , two immunotherapy drugs given together, for people with advanced colorectal cancer that has stopped responding to standard chemotherapy. The study will first check that the medication is safe and well-tolerated in a small group, then test whether this treatment can shrink tumors in a larger group of patients. This is one of the first times these two drugs have been combined and studied together in humans.
Many people with advanced colorectal cancer find that standard chemotherapy stops working after a while, leaving them with very few treatment options. This medication combination works by helping the immune system recognize and attack cancer cells, which is a different approach than traditional chemotherapy—and early research suggests it might help patients whose disease has become resistant to standard drugs.
You likely qualify if…
You likely don't qualify if…
You would come to Mount Sinai Hospital to receive the medication intravenously (through an IV) every three weeks for up to one year, or until your cancer progresses—whichever comes first. Before starting and during the study, you'll have blood samples taken, imaging scans to measure your tumors, and tumor biopsies so researchers can understand how the medication is working. The study involves both a safety phase with a small group and then a larger effectiveness phase to see if this treatment helps shrink tumors.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States